Platelet Inhibition, Revascularization, and Risk Prediction in Non-ST-elevation Acute Coronary
Syndromes diva-portal.org Digitala Vetenskapliga Arkivet Simple search Advanced search …

Acute coronary syndromes (ACS) are a major public health problem [1]. It is estimated that
costs of ACS are about 2% of health care budgets [2]. The term ACS includes a spectrum of …

The term acute coronary syndrome (ACS) refers to a spectrum of clinical conditions ranging
from acute myocardial infarction with ST elevation to minimally symptomatic myocardial …

Platelets play key physiologic roles in the hemostatic response to vascular injury. But
thrombi that form in the absence of vessel wall damage may either disrupt or completely …

Objective: To investigate whether the beneficial and harmful effects of platelet glycoprotein
IIb/IIIa receptor blockers in non-ST elevation acute coronary syndromes (NSTE-ACS) …

Delayed inhibition of platelets during percutaneous coronary intervention (PCI) is associated
with adverse rates of ischemic cardiovascular events in patients presenting with acute …

Objectives Upon completing this activity, participants will be able to:• Describe the role of
platelets in thrombosis and the development of ACS• Explain the association between …

Non–ST-segment elevation acute coronary syndrome (NSTE-ACS), which comprises
unstable angina and non–ST-segment elevation myocardial infarction (NSTE-MI) …

Background: The PLATelet inhibition and patient Outcomes trial (PLATO) showed that, in
patients with acute coronary syndromes (ACS), treatment with ticagrelor as compared with …

Risk stratification is crucial in guiding the acute management of non–ST-segment elevation
(NSTE) acute coronary syndromes (ACS). An early invasive strategy (catheterization …